Search Results - "López‐Vega, José Manuel"

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results by Perez, Edith A, López-Vega, José Manuel, Petit, Thierry, Zamagni, Claudio, Easton, Valerie, Kamber, Julia, Restuccia, Eleonora, Andersson, Michael

“…Pertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive metastatic breast cancer (MBC). However, alternative…”
Get full text

Pathological fracture from clinically occult breast cancer by Carrascosa, Miguel F, Fernández-Ayala, Marta, Cano Hoz, Marta, Abascal Carrera, Ismael, Casuso Sáenz, Elena, Montes-Moreno, Santiago, López-Vega, José Manuel

“…In August, 2020, a 71-year-old woman presented to the emergency department of the Hospital of Laredo (Laredo, Spain) with severe stabbing pain in her right arm…”
Get full text

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer by López-Vega, José Manuel, Álvarez, Isabel, Antón, Antonio, Illarramendi, José Juan, Llombart, Antonio, Boni, Valentina, García-Velloso, María José, Martí-Climent, Josep María, Pina, Luis, García-Foncillas, Jesús

“…This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging…”
Get full text

Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has Changed? by Riancho, Javier, Lozano-Cuesta, Pablo, Santurtún, Ana, Sánchez-Juan, Pascual, López-Vega, José Manuel, Berciano, José, Polo, José Miguel

“…In the last years different studies have reported an increase of amyotrophic lateral sclerosis (ALS) incidence, highlighting the role of the environment in…”
Get more information

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer by Martín, Miguel, Rodríguez-Lescure, Álvaro, Ruiz, Amparo, Alba, Emilio, Calvo, Lourdes, Ruiz-Borrego, Manuel, Munárriz, Blanca, Rodríguez, César A., Crespo, Carmen, de Alava, Enrique, López García-Asenjo, José Antonio, Guitián, María Dolores, Almenar, Sergio, González-Palacios, Jesús Fernando, Vera, Francisco, Palacios, José, Ramos, Manuel, Gracia Marco, Jose Manuel, Lluch, Ana, Alvarez, Isabel, Seguí, Miguel Angel, Mayordomo, José Ignacio, Antón, Antonio, Baena, José Manuel, Plazaola, Arrate, Modolell, Alfonso, Pelegrí, Amadeu, Mel, Jose Ramón, Aranda, Enrique, Adrover, Encarna, Álvarez, José Valero, García Puche, José Luis, Sánchez-Rovira, Pedro, Gonzalez, Sonia, López-Vega, José Manuel

“…Background Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the…”
Get full text

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study by MARTIN, Miguel, RUIZ, Amparo, MUNOZ-MATEU, Montserrat, DORCA RIBUGENT, Joan, LOPEZ-VEGA, José Manuel, JARA, Carlos, ESPINOSA, Enrique, MENDIOLA FERNANDEZ, César, ANDRES, Raquel, RIBELLES, Nuria, PLAZAOLA, Arrate, SANCHEZ-ROVIRA, Pedro, RUIZ BORREGO, Manuel, SALVADOR BOFILL, Javier, CRESPO, Carmen, CARABANTES, Francisco J, SERVITJA, Sonia, IGNACIO CHACON, José, RODRIGUEZ, César A, HERNANDO, Blanca, ALVAREZ, Isabel, CARRASCO, Eva, LLUCH, Ana, BARNADAS, Agustí, GONZALEZ, Sonia, CALVO, Lourdes, MARGELI VILA, Mireia, ANTON, Antonio, RODRIGUEZ-LESCURE, Alvaro, SEGUI-PALMER, Miguel Angel

“…Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients with node-positive breast cancer (BC). Currently, however, most…”
Get full text

Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy by Etxano, Jon, Insausti, Luis Pina, Elizalde, Arlette, López Vega, José Manuel, Plazaola, Arrate, Martínez, Purificación

“…Antiangiogenic drugs are being used in the treatment of locally advanced breast cancer. The effect of these drugs can be monitorized using high temporal…”
Get more information

Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study by ESTEVEZ, Laura G, CUEVAS, José Miguel, ANTON, Antonio, FLORIAN, Jesus, LOPEZ-VEGA, José Manuel, VELASCO, Amalia, LOBO, Francisco, HERRERO, Ana, FORTES, José

“…This is one of the first reports of weekly docetaxel (Taxotere) in the neoadjuvant treatment of stage II and III breast cancer. We evaluated docetaxel's…”
Get full text

The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis by Andersson, Michael, López-Vega, José Manuel, Petit, Thierry, Zamagni, Claudio, Donica, Margarita, Kamber, Julia, Perez, Edith A.

“…Abstract only…”
Get full text

A multicenter randomized phase II trial of granulocyte‐colony stimulating factor‐supported, platinum‐based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma by Hidalgo, Manuel, Mendiola, César, López‐Vega, José Manuel, Castellano, Daniel, Mendez, Miguel, Batiste‐Alenton, Eduardo, López‐Brea, Marta, Belon, Joaquín, Batista, Jose N., Cortés‐Funes, Hernán

“…BACKGROUND The purpose of this study was to analyze whether the addition of granulocyte‐colony stimulating factor (G‐CSF) to platinum‐based combination…”
Get full text

Abstract P2-13-17: Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo I-III breast cancer registry (1990-2001) by López-Tarruella, Sara, Escudero, María José, Martín, Miguel, Jara, Carlos, Guerrero, Ángel, Lluch, Ana, Santaballa, Ana, Martínez del Prado, Purificación, Lao, Juan, Alba, Emilio, Fernández, Antonio, Andrés, Raquel, Llombart, Antonio, Batista, Norberto, Porras, Ignacio, López-Vega, José Manuel, Adrover, Encarna, Calvo, Lourdes, Pollán, Marina, Carrasco, Eva

“…Introduction: Retrospective data from institutional series and population-based databases have suggested a potential benefit of the primary tumor (PT) surgery…”
Get full text

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry) by Lopez-Tarruella, Sara, Escudero, M. J., Pollan, Marina, Martín, Miguel, Jara, Carlos, Bermejo, Begoña, Guerrero-Zotano, Angel, García-Saenz, José, Santaballa, Ana, Alba, Emilio, Andrés, Raquel, Martínez, Purificación, Calvo, Lourdes, Fernández, Antonio, Batista, Norberto, Llombart-Cussac, Antonio, Antón, Antonio, Lahuerta, Ainhara, de la Haba, Juan, López-Vega, José Manuel, Carrasco, E.

“…The debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach’s outcomes in…”
Get full text

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study by Martín, Miguel, Ruiz Simón, Amparo, Ruiz Borrego, Manuel, Ribelles, Nuria, Rodríguez-Lescure, Álvaro, Muñoz-Mateu, Montserrat, González, Sonia, Margelí Vila, Mireia, Barnadas, Agustí, Ramos, Manuel, Del Barco Berron, Sonia, Jara, Carlos, Calvo, Lourdes, Martínez-Jáñez, Noelia, Mendiola Fernández, César, Rodríguez, César A, Martínez de Dueñas, Eduardo, Andrés, Raquel, Plazaola, Arrate, de la Haba-Rodríguez, Juan, López-Vega, Jose Manuel, Adrover, Encarna, Ballesteros, Ana Isabel, Santaballa, Ana, Sánchez-Rovira, Pedro, Baena-Cañada, José M, Casas, Maribel, del Carmen Cámara, María, Carrasco, Eva Maria, Lluch, Ana

“…Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a…”
Get full text

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain by Alba, Emilio, Ciruelos, Eva, López, Rafael, López-Vega, José Manuel, Lluch, Ana, Martín, Miguel, Muñoz, Montserrat, Sánchez-Rovira, Pedro, Seguí, Miguel Ángel, Liria, Marta Rubio, Pérez-Alcántara, Ferran

“…The COSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard…”
Get more information

Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer by Laura G. Estévez, José Miguel Cuevas, Antonio Antón, Jesús Florián, José Manuel López-Vega, Amalia Velasco, Francisco Lobo, Ana Herrero, José Fortes

“…Purpose: This is one of the first reports of weekly docetaxel (Taxotere) in the neoadjuvant treatment of stage II and III breast cancer. We evaluated…”
Get full text

El síndrome anorexia caquexia by Fernando Rivera, José Manuel López-vega, Carlos López, Ana López, Mª Eugenia Vega, Jaime Sanz

“…The anorexia-cachexia syndrome is a paraneoplasic, metabolic disorder characterized by the appearance of appetite decrease, loss of weight and muscular mass…”
Get full text

Análisis farmacoeconómico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject®) en España by Rubio-Terrés, Carlos, López, Ángel Fernández, Montero, Aída Fernández, Vega, José Manuel López, Castelao, Alberto Martínez, Gisbert, Javier P., Valera, Manuel Quirós, Baines, Juan Pablo Ordovás

“…Resumen Objetivo : La duración de la administración intravenosa (i.v.) con hierro carboximaltosa (Ferinject®) es menor que con otros hierros inyectables…”
Get full text

Quimioterapia complementaria tras una metastasectomía by López Vega, José Manual

Get full text

Carboplatin: an active drug in metastatic breast cancer by Martín, M, Díaz-Rubio, E, Casado, A, Santabárbara, P, López Vega, J M, Adrover, E, Lenaz, L

“…The study was undertaken to assess the antitumor activity of carboplatin 400 mg/m2 intravenously every 4 weeks in metastatic breast cancer (MBC). Thirty-four…”
Get more information

Comments to an editorial on vinflunine by López Vega, José Manuel, González, Emilio Esteban

Get more information